SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parenteral Drugs surges on commencing production from newly established plant

31 Mar 2014 Evaluate

Parenteral Drugs (India) is currently trading at Rs. 29.95, up by 0.85 points or 2.92% from its previous closing of Rs. 29.10 on the BSE.

The scrip opened at Rs. 29.90 and has touched a high and low of Rs. 30.55 and Rs. 29.90 respectively. So far 2351 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 125.00 on 17-May-2013 and a 52 week low of Rs. 25.65 on 19-Feb-2014.

Last one week high and low of the scrip stood at Rs. 32.40 and Rs. 28.80 respectively. The current market cap of the company is Rs. 89.30 crore.

The promoters holding in the company stood at 73.28 % while Institutions and Non-Institutions held 0.76 % and 25.96 % respectively.

Parenteral Drugs (India) has commenced the production from its newly established plant of Punjab Formulations, a subsidiary of the company, situated at Ahirana village, Hoshiarpur district in state of Punjab. Further, the production activity of previous plant situated at Jalandar in Punjab state has been discontinued.

Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. It is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose.

Parenteral Drugs Share Price

3.39 0.00 (0.00%)
21-Aug-2023 18:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×